Who is the CEO of Prestige BioPharma?

According to the DART company overview, Prestige BioPharma's representative director is 박소연 (name as registered in Korean). The company was founded on 2015-07-13.

Where is Prestige BioPharma listed?

Prestige BioPharma trades on the Korea Exchange KOSPI market under the ticker 950210. Its fiscal year ends in June.

What were Prestige BioPharma's latest quarterly results?

In Q1 2026, Prestige BioPharma reported revenue of ₩0m and an operating loss of ₩18m. Figures come from reports filed on DART.

Does Prestige BioPharma pay a dividend?

Prestige BioPharma did not pay a cash dividend for fiscal 2025, according to its annual report.

Does Prestige BioPharma have any recent filing signals?

Signals detected automatically from DART filings and quarterly results: 4 quarters of losses (operating loss in each of the last four quarters). These are factual flags, not investment advice.

Which companies are in the same industry as Prestige BioPharma?

Under the Korean Standard Industrial Classification recorded on DART, Prestige BioPharma is grouped with 53 other listed companies in medical & pharmaceutical r&d. The most covered in Korean news over the past 30 days are Alteogen, D&D Pharmatech and LigaChem Biosciences.

Prestige BioPharma KRX:950210KOSPI

프레스티지바이오파마 · Korean news coverage and regulatory filings, organized.

한국어

Articles, 24h0

Articles, 7 days1

DART filings, 7 days0

Articles tracked28since Sep 11

In Q1 2026, Prestige BioPharma reported revenue of ₩0m and an operating loss of ₩18m. Prestige BioPharma (프레스티지바이오파마) appeared in 1 Korean news article and 0 DART filings over the past seven days. Coverage peaked on Nov 10 with 1 article. It was most often mentioned alongside SyntekaBio.

Filing signals 4 quarters of losses Screener

Prestige BioPharma quarterly results consolidated, KRW

Quarter	Revenue	YoY	Operating profit	Net income
Q1 2026	₩0m	–	−₩18m	−₩21m
Q4 2025	₩5m	+140.6%	−₩13m margin −242.4%	−₩14m
Q3 2025	₩2m	+1.9%	−₩18m	−₩15m
Q2 2025 derived	–	–	−₩10m	−₩6m
Q1 2025	–	–	−₩11m	₩33m
Q4 2024	₩2m	–	−₩15m	−₩16m
Q3 2024	₩2m	–	−₩11m	−₩8m
Q2 2024 derived	–	–	−₩7m	−₩9m

Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases. Margin is operating profit divided by revenue — see operating margin.

Prestige BioPharma top stories 2 weeks, by number of outlets

1
Prestige Biopharma and Synteca Bio expand research efficiency by 'integrating AI technology'
1 outlets · 1 articlesFirst report Nov 10 09:04 팍스경제TVSyntekaBio

Latest Prestige BioPharma news Korean headlines

Nov 1009:04

Prestige Biopharma and Synteca Bio expand research efficiency by 'integrating AI technology'
팍스경제TVSyntekaBio
Oct 2616:15

Prestige Biopharma presents chitosan hydrogel-based subcutaneous drug delivery research at American 'AAPS 2026'
더스탁
Oct 2613:40

MajorPrestige Biopharm unveils subcutaneous injection platform non-clinical data, exploring technology transfer
뉴스락Licensing deal
Oct 2610:08

Prestige Biopharma presents non-clinical research on chitosan hydrogel-based SC formulation at US AAPS
팍스경제TV
Oct 2311:06

MajorPrestige Biopharma presents Phase 1 clinical results of pancreatic cancer candidate at ESMO
뉴스락Clinical trial
Oct 2309:41
Prestige Biopharma unveils Phase 1 data for pancreatic cancer drug PBP1510 at ESMO
PRESS9
2 more on this story · 2 outlets
- Prestige Biopharma presents Phase 1 clinical results of pancreatic cancer drug PBP1510 at ESMO메디컬투데이 · Oct 23 12:39
- Prestige Biopharma presents Phase 1 clinical results of pancreatic cancer drug at ESMO파이낸셜포스트 · Oct 23 15:30
Oct 2309:05

Prestige Biopharma discusses PBP1510 follow-up development strategy at ESMO
팍스경제TV
Oct 712:17

Prestige Biopharma expands Tuosnew global territory, sourcing partners at CPHI
메디컬투데이글로벌테크놀로지
Oct 710:17
Prestige Biopharma participates in global trade show CPHI Milan 2026
더바이오글로벌테크놀로지
1 more on this story · 1 outlets
- Pamicell participates in CPHI Milan 2026, strengthening global cooperation뉴스핌 · Oct 7 09:34
Oct 710:05

Prestige Biopharma participates in global trade show CPHI Milan 2026
더스탁
Oct 709:04
Prestige Biopharma to develop new commercialization partners for Tuosnew at CPHI Milan 2026
팍스경제TV
1 more on this story · 1 outlets
- Prestige Biopharma to discover new Tuosnew partners at CPHI Milan 2026뉴스핌 · Oct 7 09:34
Oct 709:00

Prestige Biopharma seeks new partners for Tuosnew at CPHI, expanding cooperation
PRESS9
Oct 708:26

Prestige Biopharma expands Tuosnew sales channels and new drug partnerships
메디파나뉴스
Oct 109:08

Prestige Biopharma IDC Research Division Head Kang Tae-heung at Business Spotlight: Additional pipeline ready, driving research achievements
팍스경제TV
Sep 3017:08

Prestige Biopharma appoints Dr. Neil O'Connor, CMC head, as executive director
PRESS9
Sep 3014:27
Prestige Biopharma appoints J&J-trained antibody drug CMC expert Neil O'Connor as director
팍스경제TV
1 more on this story · 1 outlets
- Prestige Biopharma appoints global CMC expert Dr. Neil O'Connor as executive directorEBN · Sep 30 16:13
Sep 2816:39

MajorPrestige Biopharma obtains Tuosnew product approval in Brazil, expanding South America presence
EBNRegulatory approval
Sep 2815:15

MajorPrestige Biopharma records 15 billion won impairment loss on European product approval
뉴스토마토Regulatory approval
Sep 2808:28

MajorPrestige Biopharma obtains Tuosnew product approval in Brazil, launching locally with Dr. Reddy's
팍스경제TVRegulatory approval
Sep 2808:26

Prestige Biopharma R&D costs surge 76 percent, raw material costs increase tenfold
PRESS9
Sep 2306:50

Prestige Biopharma recognizes first Tuosnew royalty revenue, reflecting commercialization achievements in earnings
메디코파마
Sep 2213:58

MajorPrestige Biopharma aims to file PBP1710 clinical trial plan by year-end, visualizing new candidate substances
PRESS9Clinical trial
Sep 1809:13

MajorPrestige Biopharma obtains Tuosnew product approval in Trinidad and Tobago in Central America, accelerating market supply
팍스경제TVRegulatory approval
Sep 1616:15

Prestige Biopharma IDC acquires ISO 14001 and 45001 certifications simultaneously, establishing quality, environment and occupational safety management system
팍스경제TV

Articles per day 2 weeks

110

Company profile

CEO: 박소연
Industry: Medical & pharmaceutical R&D
Founded: 2015-07-13
Fiscal year-end: June
Head office: 21 BIOPOLIS
Website: prestigebiopharma.com
Quotes & chart: Naver Securities (Korean)

From the DART company overview.

Same industry Medical & pharmaceutical R&D

All in industry

Company	Latest quarter op. profit	Articles 30d
Alteogen	–	255
D&D Pharmatech	−₩13.6bn	72
LigaChem Biosciences	−₩50.4bn	69
Curocell	−₩7.7bn	51
SillaJen	–	44
OliX Pharmaceuticals	–	42
Qurient	−₩7.0bn	41
GI Innovation	–	41

Compare Prestige BioPharma side by side with these companies

Prestige BioPharma DART filings

Sep 2916:32

Notification of appointment, dismissal and change of external auditor for listed foreign corporation on securities market
Other
Sep 2916:21

Regular shareholders meeting results
Other
Sep 2916:14

Report on appointment, dismissal or resignation of independent directors
Other
Sep 2312:33

Correction: Business report (2026.06)
Other
Sep 2207:30

Business report (2026.06)
Other
Sep 2118:12

Audit report submission
Other
Sep 1416:39

Shareholders meeting convocation resolution
Other
Sep 1415:05

Notice of shareholders' meeting
Other

Mentioned alongside 2 weeks

1 SyntekaBioKOSDAQ 1

Prestige BioPharma FAQ

Who is the CEO of Prestige BioPharma?: According to the DART company overview, Prestige BioPharma's representative director is 박소연 (name as registered in Korean). The company was founded on 2015-07-13.
Where is Prestige BioPharma listed?: Prestige BioPharma trades on the Korea Exchange KOSPI market under the ticker 950210. Its fiscal year ends in June.
What were Prestige BioPharma's latest quarterly results?: In Q1 2026, Prestige BioPharma reported revenue of ₩0m and an operating loss of ₩18m. Figures come from reports filed on DART.
Does Prestige BioPharma pay a dividend?: Prestige BioPharma did not pay a cash dividend for fiscal 2025, according to its annual report.
Does Prestige BioPharma have any recent filing signals?: Signals detected automatically from DART filings and quarterly results: 4 quarters of losses (operating loss in each of the last four quarters). These are factual flags, not investment advice.
Which companies are in the same industry as Prestige BioPharma?: Under the Korean Standard Industrial Classification recorded on DART, Prestige BioPharma is grouped with 53 other listed companies in medical & pharmaceutical r&d. The most covered in Korean news over the past 30 days are Alteogen, D&D Pharmatech and LigaChem Biosciences.